Literature DB >> 638030

The significance of secondary gram-negative coliform infection of the lungs of mice with influenzal pneumonitis.

S J Yealland, R B Heath.   

Abstract

Influenza-virus-induced pneumonia of mice was consistently shown to be associated with secondary infection with coliform organisms. Treatment with gentamicin effectively sterilized the lungs of these mice but had no effect on either mortality or extent of the pneumonic process. The significance of these findings is discussed.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 638030      PMCID: PMC2041315     

Source DB:  PubMed          Journal:  Br J Exp Pathol        ISSN: 0007-1021


  4 in total

1.  SYNERGISTIC ACTIVITY BETWEEN PR8 INFLUENZA VIRUS AND STAPHYLOCOCCUS AUREUS IN THE GUINEA PIG.

Authors:  R J JANSSEN; W A CHAPPELL; P J GERONE
Journal:  Am J Hyg       Date:  1963-11

2.  Synergistic effect in viral-bacterial infection. I. Combined infection of the respiratory tract in mice with parainfluenza virus and Hemophilus influenza.

Authors:  M Degré; L A Glasgow
Journal:  J Infect Dis       Date:  1968-12       Impact factor: 5.226

3.  The pathogenesis of infections of the mouse caused by virulent and avirulent variants of an influenza virus.

Authors:  S Raut; J Hurd; G Blandford; R B Heath; R J Cureton
Journal:  J Med Microbiol       Date:  1975-02       Impact factor: 2.472

4.  Secondary respiratory infection in hospital patients: effect of antimicrobial agents and environment.

Authors:  J R Philp; R C Spencer
Journal:  Br Med J       Date:  1974-05-18
  4 in total
  3 in total

Review 1.  Pathogenicity of influenza virus.

Authors:  C Sweet; H Smith
Journal:  Microbiol Rev       Date:  1980-06

2.  Histopathological changes in the lungs of influenza-infected mice superinfected with Staphylococcus aureus.

Authors:  I D Gardner; T M Kung
Journal:  Br J Exp Pathol       Date:  1980-08

3.  Tracheal function during influenza infections.

Authors:  K M Nugent; E L Pesanti
Journal:  Infect Immun       Date:  1983-12       Impact factor: 3.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.